documented protocols
Acetyl octapeptide-3: what is documented about dosing
No study of this ingredient on its own has been published, so no figure below comes from one. This page explains what that means rather than filling the gap.
- Primary sources Registry records and papers are read at the source, not through summaries. Read the methodology
- Every claim graded Each claim about what a compound does carries an evidence tier and a numbered citation. How grades derive
- Sells nothing No cart, no price, and no product page anywhere on this site. Conflict disclosure
- Corrections logged Errors are fixed and recorded in a permanent public log, never edited away. Corrections log
This is a lawfully sold cosmetic ingredient. What would normally go here is the concentration a study used, and no study of this ingredient alone exists to have used one.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
What this page reports, and what it does not
We report what has been documented. We do not prescribe what should be done.
Nothing here is a dosing recommendation. Statements about dosing reflect community and research reports only.
No trial established an amount of Acetyl octapeptide-3 for a person. Most of the rows below record what a published study gave to its animals or its cells, in the model that study built, with the species and the route named on the line. One row records that other figures circulate in community write-ups, and that this site does not republish them. Nothing here is a protocol, nothing here is scaled for a person, and this site publishes no preparation steps, no administration technique and no equipment. The reasoning is in the editorial policy.
Commonly cited protocols (extrapolated, not validated)
| Study | What was given | Frequency | Duration | Notes |
|---|---|---|---|---|
| Any study of this peptide alone | Nothing documented | Nothing documented | Nothing documented | No such study was found in PubMed or the registry |
| The two microneedle patch studies | Not stated for this peptide in either abstract | Overnight in one, weekly application over 12 weeks in the other | 28 days and 12 weeks | Four or five actives per patch, so no figure is attributable to this ingredient |
| Any human use | Nothing documented | Nothing documented | Nothing documented | No registered study of this ingredient exists |
Figures circulate for this ingredient in finished products. They come from suppliers and from product marketing rather than from a study, and this site does not reproduce them as guidance.
The reason there is nothing to reproduce is worth stating rather than working around. A concentration is only informative alongside a result, and no result attributable to this ingredient has been published.
Nothing here is a use instruction. Talk to a licensed clinician about anything concerning your health.
Our takeThere is no documented figure for this ingredient from any study of it, and there is no way to derive one from studies of mixtures.,Talk to a licensed clinician about anything concerning your health.
Main routes people compare
Applied to the skin
The route the ingredient is sold for. No published study has measured what this peptide does or where it goes by this route.
Microneedle patch
Both published studies naming this peptide used a patch of dissolving needles that punctures the outer layer of skin. In each case the patch also carried three or four other actives, so neither result is attributable to this ingredient, and in neither case does the route match how it is sold.
What is said about cycle length and timing
No cycle appears anywhere in the record for this ingredient, and the concept does not apply to a cosmetic applied to the skin.
Talk to a licensed clinician about anything concerning your health.
What has been measured about safety
A reader weighing what other people report giving usually wants the other half of the record next. What has been measured about Acetyl octapeptide-3, and what has never been studied reports what has actually been measured, in what system and over what period, and the questions no published study has put.
Frequently asked questions
What concentration is this ingredient used at?
No study of it on its own has been published, so no figure comes from one. The two published studies of mixtures containing it do not state a concentration for it in their abstracts.
Where do the figures circulating online come from?
Supplier material and product marketing rather than a published study. This site does not reproduce them as guidance.
Can a figure be taken from the peptide it extends?
No. They are different molecules, no study compares them, and the difference in size is the one property the comparison is sold on.
References
- Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024. PMID 39082657 DOI 10.5021/ad.23.136
- Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020. PMID 31134751 DOI 10.1111/jocd.13009
- Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID 40565185 DOI 10.3390/ijms26125722
- Mortazavi SM, Moghimi HR. Skin permeability, a dismissed necessity for anti-wrinkle peptide performance. Int J Cosmet Sci. 2022. PMID 35302659 DOI 10.1111/ics.12770
- Kraeling ME, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015. PMID 24754410 DOI 10.3109/15569527.2014.894521
- Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002. PMID 18498523 DOI 10.1046/j.1467-2494.2002.00153.x
- Skibska A, Perlikowska R. Signal Peptides - Promising Ingredients in Cosmetics. Curr Protein Pept Sci. 2021. PMID 34382523 DOI 10.2174/1389203722666210812121129
- Johnson W Jr, Bergfeld WF, Belsito DV, Cohen DE, Klaassen CD, Liebler DC, Marks JG Jr, Peterson LA, Shank RC, Slaga TJ, Snyder PW, Fiume M, Heldreth B. Safety Assessment of Acetyl Hexapeptide-8 Amide as Used in Cosmetics. Int J Toxicol. 2025. PMID 40673537 DOI 10.1177/10915818251340391
- US National Library of Medicine. PubMed, searched for the term acetyl octapeptide-3 on 23 August 2026, repeating a search first run on 2 August 2026. Both returned the same two records, PMID 39082657 and PMID 31134751, each a study of a multi-ingredient microneedle patch. No record testing the peptide on its own was returned. Searches for acetyl octapeptide and for a Cosmetic Ingredient Review safety assessment of the octapeptide returned no record of either. PubMed. 2026. Source document
- ClinicalTrials.gov. Registry sweep for acetyl octapeptide-3, acetyl octapeptide-8 and SNAP-8 peptide, run through the v2 API on 23 August 2026. Each of the three queries returned no record, at any phase, in any country. The same sweep returned six records for acetyl hexapeptide-8, which are covered on that compound's page. ClinicalTrials.gov. 2026. ClinicalTrials.gov
- United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
- Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 23 August 2026. United States Code. 2026. Source document
- Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 23 August 2026. Electronic Code of Federal Regulations. 2026. Source document